CB4211 - NASH and Obesity
In 2021, we announced positive topline data from our Phase 1a/1b study of CB4211, which is under development for the treatment of NASH and obesity. This study met its primary endpoints as CB4211 was well-tolerated and appeared safe with no serious adverse events. Evaluation of the exploratory endpoints in the 1b portion of the trial showed significant reductions from baseline in key biomarkers of liver damage, ALT and AST, and in glucose levels in the CB4211 group compared to placebo after four weeks of treatment, with a trend towards lower body weight. In addition, there was a measurable reduction in the level of liver fat.
CB4211 is a first-in-class therapeutic that is a novel and improved analog of MOTS-c, a naturally occurring mitochondrial derived peptide (MDP). MOTS-c was discovered in 2012 by CohBar founder Dr. Pinchas Cohen and his academic collaborators and has been shown to play an important role in the regulation of metabolism. Consistent with our recent clinical data, CB4211 has demonstrated significant therapeutic potential in preclinical models of NASH and obesity. View Candidate